与肥胖心脏病患者的类似药物相比, Wegovy将重大心脏病风险降低57%。 Wegovy® reduced major heart risks by 57% compared to a similar drug in obese patients with heart disease.

诺沃·诺迪斯克(Novo Nordisk)制作的Wegovy将心脏病发作、中风或死亡的风险降低57%, Wegovy®, made by Novo Nordisk, reduced the risk of heart attack, stroke, or death by 57% compared to tirzepatide in a study of people with obesity and heart disease. 该研究在欧洲心脏病学学会大会上提出,表明Wegovy的好处是其活性成份即酸所独有的,可能不适用于其他类似治疗。 Presented at the European Society of Cardiology Congress, the study suggests that Wegovy's benefits are unique to its active ingredient, semaglutide, and may not apply to other similar treatments. 研究结果突出了Wegovy在现实世界环境中的具体心脏保护效果。 The findings highlight the specific heart-protective effects of Wegovy in real-world settings.